Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471146 · ClinicalTrials.gov registry record · Phase 3
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT00471146 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 630 participants.
The verdict
NCT00471146, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
Interventions
- DRUG placebo
- DRUG Gemcitabine
- DRUG AG-013736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471146
The ClinicalTrials.gov registry entry for NCT00471146 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00471146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471146 about?
NCT00471146 is a clinical study titled "Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.". The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
What is the current status of trial NCT00471146?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2007-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00471146?
The interventions under investigation include: placebo (DRUG), Gemcitabine (DRUG), AG-013736 (DRUG).
Who is sponsoring clinical trial NCT00471146?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.